Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Profit After Tax: 2020-2025

Historic Profit After Tax for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Profit After Tax rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 18.95%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Per Silence Therapeutics' latest filing, its Profit After Tax stood at -$21.0 million for Q3 2025, which was up 23.38% from -$27.4 million recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Profit After Tax peaked at $12.3 million during Q4 2024, and registered a low of -$13.6 billion during Q1 2021.
  • Over the past 3 years, Silence Therapeutics' median Profit After Tax value was -$15.4 million (recorded in 2023), while the average stood at -$16.0 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first skyrocketed by 224.58% in 2024, then plummeted by 1,134.00% in 2025.
  • Over the past 5 years, Silence Therapeutics' Profit After Tax (MRQ) stood at -$6.4 million in 2021, then tumbled by 48.71% to -$9.6 million in 2022, then decreased by 3.03% to -$9.9 million in 2023, then surged by 224.58% to $12.3 million in 2024, then crashed by 270.36% to -$21.0 million in 2025.
  • Its last three reported values are -$21.0 million in Q3 2025, -$27.4 million for Q2 2025, and -$28.5 million during Q1 2025.